IDO1 and glioblastoma: Indeed, IDO1 inhibitors are currently in clinical trials for GBM [147, 148] and the kynurenine/tryptophan ratio is a promising prognostic and predictive biomarker in GBM patients treated with surgery and immunotherapy [149].